https://www.selleckchem.com/pr....oducts/17-AAG(Geldan
Our results showed that hippocampal microinjection of ceftriaxone, as an activator of GLT-1, reduced some signs of morphine withdrawal, such as activity, diarrhea, head tremor, freezing, and ptosis. It seems that hippocampal GLT-1 can be affected by chronic morphine administration and involved in morphine dependence. Therefore, its activation may reduce morphine side effects by reducing hippocampal glutamate. Effective inhibition of thrombosis without generating bleeding risks is a major challenge in medicine. Accumulating
Like
Comment
Share
